Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Cash flows from operating activities:    
Net loss $ (1,360) $ (1,963)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock compensation expense 175 312
Fair value adjustment of common stock warrants (10) (3)
Depreciation 15 1
Loss on disposal of property and equipment 0 17
Amortization of intangible assets 105 20
Accrued interest on note receivable (17) (17)
Accrued interest promissory note 3 0
Deferred tax liability 0 (336)
Tax benefit related to intangibles (41) 0
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (8) (57)
Accounts payable, accrued expenses and other liabilities 40 2
Current assets and liabilities from discontinued operations, net (139) 316
Net cash used in operating activities (1,237) (1,708)
Cash flows from investing activities:    
Acquisition of property and equipment (11) (71)
Cash received from acquisition 0 476
Issuance of note receivable 0 (300)
Net cash provided by (used in) investing activities (11) 105
Net decrease in cash and cash equivalents (1,248) (1,603)
Cash and cash equivalents at beginning of period 4,039 [1] 7,820
Cash and cash equivalents at end of period 2,791 6,217
Supplemental disclosure of non-cash activities:    
Shares issued in CollabRx acquisition 0 932
Note receivable used as consideration for CollabRx acquisition 0 300
Promissory note issued in CollabRx acquisition 0 500
Fair value of assets acquired in CollabRx acquisition 0 2,253
Liabilities assumed in CollabRx acquisition $ 0 $ 997
[1] Derived from the Company's audited consolidated financial statements.